The Vanguard Group Discloses Interest in Avadel Pharmaceuticals

The Vanguard Group, Inc. has submitted a Form 8.3 under the rules of the Irish Takeover Panel, revealing its significant stake in Avadel Pharmaceuticals plc. The form, dated February 6, 2026, details the firm's interests in securities related to Avadel, holding 5,797,771 ordinary shares at $0.01 each, which represents 5.95% of the total shares.

The disclosure includes recent transactions, with Vanguard purchasing 802 shares and selling 2,532 shares, both at the unit price of 21.69 USD. There are no cash-settled or stock-settled derivatives, nor are there any reported indemnity arrangements or options impacting these securities. The document ensures transparency under the 2022 Takeover Rules.